Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2019 Jul 20;15(3):390–399. doi: 10.1007/s11481-019-09864-z

Figure 4. Intranasal delivery of lincRNA-Cox2-siRNA loaded EVs decreases LPS-induced microglial proliferation in mice.

Figure 4.

(A) Biodistribution of PKH26 labeled EVs in the tissues of mice using IVIS (n=3). (B) Immunostaining of the brain sections of mice administered PKH26-labeled EVs for the microglial marker Iba1 (green). Representative micrographs are shown (original magnification ×40). Scale bar represents 10 μm. (C) Fluorescent images of mouse brain section triple-labeled for lincRNA-Cox2 and microglial cells (Iba-1) with DAPI. (D) Fluorescent images of Iba-1, BrdU, and DAPI in the mouse thalamus. (E) Quantification of Iba-1 and BrdU cofluorescence of sections as in (C).Scale bar represents 25μm in (C) and (D). Data are mean ± SEM of at least three independent experiments. Nonparametric Kruskal-Wallis one-way ANOVA followed by Dunn’s post hoc test was used to determine the statistical significance between multiple groups. *p < 0.05 versus control. #p < 0.05 versus control-siRNA + LPS group.